Trastuzumab biosimilar, recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) that has been shown to inhibit the proliferation of HER2 overexpressing cancer cells. Indications: HER2 positive breast cancer (early and metastatic forms), metastatic adenocarcinoma of the stomach or gastro-esophageal junction with HER2 overexpression. Currently > 85 000 patients treated, > 1 000 000 vials sold, marketed in 27 countries.

*Numbers of vials/patients treated relevant as of January 2022. The calculation of patients is based on the average recommended doses, average patient weight, and the approximate duration of therapy